Nuveen
CRMD icon

Nuveen’s CorMedix CRMD Stock Holding History

Nuveen’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
185,274
+10,038
+6% +$79.3K ﹤0.01% 2749
2026
Q1 		$1.19M Buy
175,236
+1,254
+0.7% +$9.27K ﹤0.01% 2500
2025
Q4 		$2.02M Sell
173,982
-521,742
-75% -$5.77M ﹤0.01% 2293
2025
Q3 		$8.09M Sell
695,724
-772,997
-53% -$9.35M ﹤0.01% 1669
2025
Q2 		$18.1M Buy
1,468,721
+1,194,040
+435% +$13.2M 0.01% 1168
2025
Q1 		$1.69M Buy
274,681
+102,703
+60% +$1.06M ﹤0.01% 2403
2024
Q4 		$1.39M Buy
171,978
+1,679
+1% +$16.8K ﹤0.01% 2544
2024
Q3 		$1.38M Hold
170,299
– – ﹤0.01% 2611
2024
Q2 		$737K Buy
170,299
+20,619
+14% +$105K ﹤0.01% 2853
2024
Q1 		$635K Sell
149,680
-91,801
-38% -$318K ﹤0.01% 2890
2023
Q4 		$908K Buy
241,481
+84,656
+54% +$291K ﹤0.01% 2778
2023
Q3 		$580K Sell
156,825
-40,210
-20% -$160K ﹤0.01% 2796
2023
Q2 		$781K Buy
+197,035
New +$975K ﹤0.01% 2764
2022
Q2 		– Sell
-177,925
Closed -$880K – 3293
2022
Q1 		$880K Buy
177,925
+1,329
+0.8% +$6.08K ﹤0.01% 2853
2021
Q4 		$850K Sell
176,596
-23,054
-12% -$114K ﹤0.01% 2908
2021
Q3 		$932K Sell
199,650
-26,815
-12% -$156K ﹤0.01% 3008
2021
Q2 		$1.55M Buy
226,465
+29,241
+15% +$233K ﹤0.01% 2818
2021
Q1 		$1.97M Sell
197,224
-16,741
-8% -$176K ﹤0.01% 2630
2020
Q4 		$1.59M Buy
213,965
+80,257
+60% +$546K ﹤0.01% 2622
2020
Q3 		$806K Buy
133,708
+11,792
+10% +$59.2K ﹤0.01% 2778
2020
Q2 		$768K Sell
121,916
-66,009
-35% -$306K ﹤0.01% 2734
2020
Q1 		$675K Buy
187,925
+26,326
+16% +$149K ﹤0.01% 2665
2019
Q4 		$1.18M Buy
161,599
+100,158
+163% +$612K ﹤0.01% 2626
2019
Q3 		$392K Sell
61,441
-105,100
-63% -$883K ﹤0.01% 3007
2019
Q2 		$1.49M Buy
+166,541
New +$1.31M ﹤0.01% 2569

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Oberweis Asset Management
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen's CRMD Position: Q2 2026 in Review

Nuveen increased its CorMedix (CRMD) stake by 5.7% in Q2 2026, buying an estimated $79.3K and bringing the position to 185,274 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

Nuveen first reported a position in CRMD in Q2 2019 and has held it in 25 quarters since. The position peaked at $18.1M in Q2 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Nuveen held 185,274 shares of CorMedix worth $1.45M as of Q2 2026.
  • Nuveen bought 10,038 CorMedix shares in Q2 2026, an estimated $79.3K.
  • CorMedix made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2749 holding.
  • Nuveen first reported a position in CorMedix in Q2 2019 and has held it in 25 quarters since.
  • Nuveen's CorMedix position peaked at $18.1M in Q2 2025.
  • 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.